# US 2022/0016048 A1 · Cannabidiol-type cannabinoid compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016048 A1
- Document ID: US20220016048A1
- Status: Published application
- Kind: A1
- Application number: 17/296,066
- Filed: 2019-11-20
- Published: 2022-01-20
- Earliest claimed: 2018-11-21
- Assignees: GW Research Limited
- Applicants: GW Research Limited
- Inventors: Geoffrey GUY; Volker KNAPPERTZ; Benjamin WHALLEY; Royston GRAY; Jacqueline CILIA; Amesha PATEL; Hannah STRAKER
- Web page: https://patentgrep.com/patent/US20220016048A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/3482: {Cannabis}
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C4 (CBD-C4), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means. Disclosed herein are data which demonstrate the efficacy of CBD-C4 in models of disease. In addition, a method for the production of CBD-C4 is described.

## Claims

### Claim 1

Cannabidiol-C4 (CBD-C4) for use as a medicament.

### Claim 2 (depends on 1)

CBD-C4 for use according to claim 1, wherein the CBD-C4 is in the form of a plant extract.

### Claim 3 (depends on 2)

CBD-C4 for use according to claim 2, wherein the CBD-C4 is in the form of a highly purified plant extract.

### Claim 4 (depends on 3)

CBD-C4 for use according to claim 3, wherein the CBD-C4 is comprises at least 80% (w/w) CBD-C4.

### Claim 5 (depends on 3)

CBD-C4 for use according to claim 3, wherein the CBD-C4 is comprises at least 95% (w/w) CBD-C4.

### Claim 6 (depends on 1)

CBD-C4 for use according to claim 1, wherein the CBD-C4 is in the form of a synthetic compound.

### Claim 7

CBD-C4 for use according to any of the preceding claims, wherein the dose of CBD-C4 is greater than 100 mg/kg/day.

### Claim 8

CBD-C4 for use according to any of the preceding claims, wherein the dose of CBD-C4 is less than 100 mg/kg/day.

### Claim 9

A composition for use as a medicament comprising cannabidiol-C4 (CBD-C4) and one or more pharmaceutically acceptable excipients.

### Claim 10

Cannabidiol-C4 (CBD-C4) for use in the treatment of epilepsy.

### Claim 11

Cannabidiol-C4 (CBD-C4) for use in the treatment of schizophrenia.

### Claim 12

A process for the preparation of cannabidiol-C4 (CBD-C4).
